Davis Polk advised Barclays Capital Inc. and Citigroup Global Markets Inc. as joint book-running managers in connection with an SEC-registered secondary offering of 7,883,366 ordinary shares of Jazz Pharmaceuticals plc, resulting in aggregate gross proceeds to the selling shareholders of approximately $390.7 million.

Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on identifying, developing and commercializing products that address unmet medical needs. The company has a diverse portfolio of products in the areas of narcolepsy, severe chronic pain, psychiatry and women’s health.

The Davis Polk corporate team included partner Bruce K. Dallas and associates Tyler P. Pender and Steve Valenzuela. Partner Rachel D. Kleinberg and associate William A. Curran provided tax advice. Associates Emma Maconick and Bruce Rose-Innes provided intellectual property advice. Haniya H. Mir was the legal assistant on the transaction. Members of the Davis Polk team are based in the Menlo Park and New York offices.